Boston Scientific Corporation

NYSE:BSX Lagerbericht

Marktkapitalisierung: US$72.0b

Boston Scientific Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Boston Scientific wird ein jährliches Gewinn- und Umsatzwachstum von 5.8% bzw. 5.4% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 5.5% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 16.9% betragen.

Wichtige Informationen

5.8%

Wachstumsrate der Gewinne

5.47%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum16.7%
Wachstumsrate der Einnahmen5.4%
Zukünftige Eigenkapitalrendite16.94%
Analystenabdeckung

Good

Zuletzt aktualisiert03 Aug 2026

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Seeking Alpha • Jul 30

Boston Scientific: Attempting The 2027 Reset

Summary Boston Scientific retains my buy rating with a $66 price target, reflecting 44% upside if negative earnings revisions stabilize. BSX has reset expectations, slashing guidance and acknowledging competitive pressures, particularly in WATCHMAN and electrophysiology segments. Valuation is now attractive at 13.7x forward earnings, with further upside contingent on management halting guidance cuts and delivering execution consistency. I expect achievable 2024 EPS at the high end of guidance ($3.32) and see potential for $3.69–$4.00 EPS in 2025 if operational improvements materialize. Read the full article on Seeking Alpha
Narrative-Update • Jul 28

BSX: Long-Term Pipeline And Buybacks Will Counter Watchman Uncertainty

Boston Scientific's updated analyst price target of $72.25, compared with the prior $75.00 fair value estimate, reflects a broad wave of Street target cuts as analysts factor in softer Watchman and electrophysiology expectations, while still pointing to intact fundamentals and underappreciated growth areas. Analyst Commentary Recent Street research on Boston Scientific points to a reset in expectations around Watchman and electrophysiology, while still highlighting core strengths in the broader portfolio.
Narrative-Update • Jul 14

BSX: Reset Growth Expectations Will Set Stage For Future Recovery Potential

Analyst price targets for Boston Scientific have been revised downward by roughly $25 to $30 as analysts factor in softer Watchman growth, ongoing electrophysiology headwinds, and slightly more conservative assumptions for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Recent research on Boston Scientific points to a mixed but still constructive backdrop, with many firms trimming price targets while maintaining positive ratings.
Narrative-Update • Jun 30

BSX: Clinical Pipeline Strength Will Offset Watchman Reset And Sector Headwinds

The analyst price target for Boston Scientific has been reduced by $2.10, from $77.10 to $75.00, as analysts factor in slower Watchman growth, lower utilization trends, and more conservative long term revenue and margin assumptions across the medtech sector. Analyst Commentary Recent research on Boston Scientific points to a clear split between optimism on the broader business and caution around Watchman and utilization trends.
Analyseartikel • Jun 19

Boston Scientific (BSX) Stock Could Be 54.2% Undervalued After Soft 2026 Guidance

Boston Scientific (BSX) shares have come under pressure after the company issued 2026 guidance that fell short of market expectations, with investors focusing on slowing revenue growth in its electrophysiology segment. See our latest analysis for Boston Scientific. At a share price of $45.29, Boston Scientific has seen pressure build, with the 30 day share price return down 20.28% and the year to date share price return down 52.18%. The 1 year total shareholder return is down 55.32%, pointing...
Narrative-Update • Jun 16

BSX: Clinical Pipeline And Share Repurchases Will Support Rebased Expectations

Boston Scientific's fair value estimate has been trimmed from $79.40 to $77.10, as analysts lower price targets across the sector and factor in slower Watchman growth, a more cautious utilization backdrop, and slightly reduced long term revenue and margin assumptions. Analyst Commentary Recent Street research on Boston Scientific clusters around a similar theme, with most firms trimming price targets and revisiting assumptions on growth, margins, and valuation after the latest Watchman commentary and a softer utilization backdrop.
Narrative-Update • Jun 01

BSX: Clinical Pipeline And Capital Deployment Will Support Rebased Expectations

Boston Scientific's updated analyst price target has shifted lower by about $5.80 to $79.40, as analysts factor in slower growth expectations for the Watchman franchise and slightly softer forecasts for revenue growth, profit margins, and future P/E. Analyst Commentary Recent Street research around Boston Scientific reflects a mix of optimism and caution, with most firms trimming price targets to align with updated expectations for the Watchman franchise, organic sales growth, and sector-wide medtech valuations.
Narrative-Update • May 08

BSX: Clinical Wins And Pipeline Strength Will Support Rebased Expectations

Analysts have trimmed the Boston Scientific fair value estimate from $95.75 to $85.19 after a series of price target cuts across the Street. The change reflects updated assumptions for slower revenue growth, slightly higher profit margins, and a lower forward P/E multiple.
Neues Narrative • Apr 24

Minimally Invasive Therapies And Atrial Fibrillation Treatments Will Support Steady Prospects Ahead

Catalysts About Boston Scientific Boston Scientific is a global medical technology company that develops and sells devices used in cardiology, electrophysiology, urology, endoscopy, neuromodulation and other interventional procedures. What are the underlying business or industry changes driving this perspective?
Narrative-Update • Apr 22

BSX: Clinical Trial Wins Will Offset Reset Expectations And Battery Concerns

Analysts have trimmed the fair value estimate for Boston Scientific to $95.75 from $100.31, reflecting a series of lower Street price targets and slightly more conservative assumptions on growth, profitability, and future P/E multiples. Analyst Commentary Recent research coverage on Boston Scientific has centered on a broad reset of expectations, with many firms revising price targets and, in some cases, ratings.
Neues Narrative • Apr 08

Pulsed Field Ablation And Minimally Invasive Therapies Will Reshape Long Term Procedure Volumes

Catalysts About Boston Scientific Boston Scientific develops and sells medical devices across cardiovascular, electrophysiology, neuromodulation, endoscopy, urology and related therapeutic areas worldwide. What are the underlying business or industry changes driving this perspective?
Narrative-Update • Apr 07

BSX: Clinical Wins And 2026 Outlook Will Outweigh Pacemaker Battery Concerns

Boston Scientific's analyst fair value estimate shifts modestly lower from $102.00 to about $100.31, as analysts recalibrate price targets across the group following recent clinical data, rating changes, and updated sector models. Analyst Commentary Recent Street research around Boston Scientific clusters around a common theme, with many firms trimming price targets and a smaller group highlighting potential upside tied to execution and clinical progress.
Narrative-Update • Mar 24

BSX: Reorganized Segments And 2026 Outlook Should Offset Recent Pacemaker Headlines

Analysts have trimmed the Boston Scientific fair value estimate by about $2 to $102, reflecting a series of reduced Street price targets that incorporate slightly lower revenue growth assumptions, a marginally higher discount rate, and modest tweaks to long term margin and future P/E expectations. Analyst Commentary Street research on Boston Scientific has been active, with most recent moves clustered around price target resets and list changes.
Narrative-Update • Mar 08

BSX: Reorganized Segments And 2026 Outlook Should Support Sentiment Rebound

Analysts have trimmed their blended price target on Boston Scientific by about $0.50 to roughly $104.25. This reflects updated models following the company reorganization and recent management commentary.
Narrative-Update • Feb 22

BSX: Organizational Changes Should Support Rebound As 2026 Patterns Normalize

Analysts have trimmed their average price target on Boston Scientific to $104.75 from $108.66, citing updated models that factor in recent organizational changes and management commentary following the latest earnings call. Analyst Commentary Across Wall Street, most research updates on Boston Scientific center on revised models and valuation resets rather than outright changes in long term views.
Narrative-Update • Feb 06

BSX: Execution Outperformance Should Drive Rebound As 2026 Patterns Normalize

The analyst price target for Boston Scientific has been reduced by about $17 to align with updated Street research. This reflects slightly lower revenue growth assumptions, a modestly higher discount rate, and a lower future P/E multiple, while profit margin expectations remain steady.
Neues Narrative • Jan 25

BSX after Penumbra ?

The immediate impact of the Penumbra acquisition has been somewhat heavy on the stock’s valuation for a few key reasons: * Earnings Dilution: The acquisition is expected to be dilutive to adjusted earnings per share (EPS) by approximately $0.06 to $0.08 in the first full year. Investors often react to this "EPS drag" by pulling back, which we've seen in the recent price dips.
Narrative-Update • Jan 10

BSX: Shares Should Rise On Execution Outperformance And 2026 Normalization Potential

Analysts have trimmed their Boston Scientific fair value estimate slightly to about $125.45 from $125.86, reflecting fine tuning of discount rate, revenue growth, profit margin and future P/E assumptions in light of recent price target resets and largely supportive research commentary across the MedTech sector. Analyst Commentary Recent Street research on Boston Scientific reflects generally constructive views on execution and growth, with some recalibration of targets as models are updated after quarterly results and sector wide resets.
Narrative-Update • Dec 25

BSX: Shares Will Rise On Execution Outperformance And Three Year Growth Plan

Analysts have nudged their fair value estimate for Boston Scientific slightly lower to approximately $126 per share, even as multiple firms have lifted price targets into the $124 to $136 range, citing sustained double digit revenue growth, a robust pipeline, and potential upside from recent acquisitions and Q3 outperformance. Analyst Commentary Bullish analysts largely frame Boston Scientific as a durable double digit grower with room for further multiple expansion, pointing to recent Q3 upside, raised long term targets, and a steady cadence of accretive deals as support for valuations near or above current levels.
Narrative-Update • Dec 11

BSX: Shares Will Rise On Earnings Strength And Multi Year Execution Momentum

Analysts nudged their average price target for Boston Scientific modestly higher, toward the low to mid $130 range, citing the company’s Q3 beat, accelerating Watchman adoption, confidence in multi year guidance, and a robust growth pipeline supported by strategic acquisitions like Nalu, despite some cautions on valuation and longer term growth moderation. Analyst Commentary Analyst reaction to Boston Scientific's latest results and strategic updates has been predominantly positive, with several firms raising price targets and reiterating favorable ratings, while a minority voice has started to flag valuation and medium term growth risks.
Narrative-Update • Nov 27

BSX: Shares Will Advance On Earnings Strength And Merger Execution Momentum

Boston Scientific's analyst price targets have been raised by several dollars, with most now clustered around $130 per share. Analysts highlight robust quarterly results, accelerating growth segments, and confidence in the company’s long-range outlook.
Narrative-Update • Nov 07

BSX: Shares Will See Momentum From Recent Acquisition And Execution Confidence

Boston Scientific's analyst price target has been increased modestly, with the consensus now reflecting a higher fair value in addition to ongoing confidence in robust growth prospects and recent business performance, as analysts cite solid quarterly results, improving guidance, and successful strategic acquisitions. Analyst Commentary Recent analyst research on Boston Scientific highlights both optimistic and cautious perspectives regarding the company's valuation, strategic moves, and long-term growth outlook.
Narrative-Update • Oct 24

Future Growth Plans And Acquisitions Will Drive Broader Market Expansion

Analysts have raised their price target for Boston Scientific to approximately $126, up from $124.53. They cite renewed confidence in the company’s earnings outlook, along with improvements in profit margin and future growth expectations, following strong quarterly performance.

Gewinn- und Umsatzwachstumsprognosen

NYSE:BSX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/202823,8744,2254,657N/A24
12/31/202722,3373,7393,765N/A29
12/31/202621,3663,8563,704N/A28
6/30/202620,9963,674N/AN/AN/A
3/31/202620,6143,5653,4754,341N/A
12/31/202520,0742,8983,6584,534N/A
9/30/202519,3492,7913,8444,626N/A
6/30/202518,4942,5053,5054,285N/A
3/31/202517,5542,0323,0143,812N/A
12/31/202416,7471,8532,6453,435N/A
9/30/202415,9111,7932,1632,936N/A
6/30/202415,2291,8281,8552,632N/A
3/31/202414,7071,7651,7192,477N/A
12/31/202314,2401,5701,7922,503N/A
9/30/202313,7571,1911,7362,353N/A
6/30/202313,4008611,5592,125N/A
3/31/202313,0458461,2561,774N/A
12/31/202212,6826421,0081,526N/A
9/30/202212,5675966291,197N/A
6/30/202212,3298286681,192N/A
3/31/202212,1627541,0071,528N/A
12/31/202111,8889851,3981,870N/A
9/30/202111,4701,1011,7012,065N/A
6/30/202111,1965261,9392,243N/A
3/31/202110,1222011,6041,869N/A
12/31/20209,913-1151,2191,508N/A
9/30/202010,1083,6851,2421,527N/A
6/30/202010,1573,9801,0081,386N/A
3/31/202010,7854,287N/A1,409N/A
12/31/201910,7354,700N/A1,836N/A
9/30/201910,3921,090N/A1,163N/A
6/30/201910,0771,396N/A1,162N/A
3/31/20199,9371,797N/A467N/A
12/31/20189,8231,671N/A310N/A
9/30/20189,670670N/A975N/A
6/30/20189,500521N/A926N/A
3/31/20189,267112N/A1,626N/A
12/31/20179,048104N/A1,426N/A
9/30/20178,831843N/A1,418N/A
6/30/20178,714788N/A935N/A
3/31/20178,582435N/A1,059N/A
12/31/20168,386347N/A1,182N/A
9/30/20168,09581N/A835N/A
6/30/20167,878-345N/A1,274N/A
3/31/20167,595-36N/A913N/A
12/31/20157,477-239N/A691N/A
9/30/20157,314-396N/A711N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: BSXDas prognostizierte Gewinnwachstum (5.8% pro Jahr) liegt über der Sparquote (3.5%).

Ertrag vs. Markt: BSXDie Erträge des Unternehmens (5.8% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (16.4% pro Jahr).

Hohe Wachstumserträge: BSXDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: BSXDie Einnahmen des Unternehmens (5.4% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (12.5% pro Jahr).

Hohe Wachstumseinnahmen: BSXDie Einnahmen des Unternehmens (5.4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: BSXDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (16.9%).

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/08/04 00:58
Aktienkurs zum Tagesende2026/08/03 00:00
Gewinne2026/06/30
Jährliche Einnahmen2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Boston Scientific Corporation wird von 58 Analysten beobachtet. 29 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Jasper HellwegArgus Research Company
David RescottBaird
null nullBaird